Qi Liu, Ph.D., M.S.
- Professor of Biostatistics
- Professor of Biomedical Informatics
Qi Liu, Ph.D., M.S.
- Professor of Biostatistics
- Professor of Biomedical Informatics
qi.liu@vumc.org
Research Program
Research Description
Robert Carroll, Ph.D., M.S.
- Associate Professor of Biomedical Informatics
Robert Carroll, Ph.D., M.S.
- Associate Professor of Biomedical Informatics
robert.carroll@vumc.org
Research Program
Research Description
Manus Donahue, Ph.D., M.B.A.
- Professor of Neurology
- Professor of Psychiatry and Behavioral Science
Manus Donahue, Ph.D., M.B.A.
- Professor of Neurology
- Professor of Psychiatry and Behavioral Science
m.donahue@vanderbilt.edu
Research Program
Research Description
Terunaga Nakagawa, M.D., Ph.D.
- Professor of Molecular Physiology and Biophysics
Terunaga Nakagawa, M.D., Ph.D.
- Professor of Molecular Physiology and Biophysics
terunaga.nakagawa@Vanderbilt.Edu
766 Robinson Research Building
Research Program
Research Description
Jennifer Below, Ph.D.
- Professor of Medicine
- Director, Vanderbilt Genetics Institute (VGI)
- Mary Phillips Edmonds Gray Chair
Jennifer Below, Ph.D.
- Professor of Medicine
- Director, Vanderbilt Genetics Institute (VGI)
- Mary Phillips Edmonds Gray Chair
jennifer.e.below@vanderbilt.edu
Research Program
Research Description
Eden Biltibo, M.D., M.S.C.I.
- Assistant Professor of Medicine
Eden Biltibo, M.D., M.S.C.I.
- Assistant Professor of Medicine
eden.a.biltibo@vumc.org
Research Program
Research Description
Lauren Woodard, PhD
- Assistant Professor of Nephrology
Lauren Woodard, PhD
- Assistant Professor of Nephrology
lauren.woodard@vumc.org
Research Program
Research Description
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable).
Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either:
* mFOLFOX6 alone,
* mFOLFOX6 with bevacizumab, or
* mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Tumor antigens key to improving cancer immunotherapy: study
Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.
